Dr Thomas Scriba

Country: South Africa

Institution: University of Cape Town

Research Areas: Tuberculosis vaccines, immunopathogenesis and biomarker research

Lab Website: www.satvi.uct.ac.za

Our focus is prevention of TB through vaccine development and biomarker-driven targeting of preventive therapy. We perform immunological human studies to identify immune correlates of risk of TB or of protection against TB and to understand the mechanistic underpinnings of successful immunity against M. tuberculosis. This work combines clinical study design, epidemiology, systems immunology and approaches based on high-dimensional data such as transcriptomics, proteomics and cellular immunology. We have performed 28 clinical trials of candidate TB vaccines including two recent phase 2b trials that demonstrated vaccine efficacy and have discovered and validated several immune correlates of risk of TB, which are currently in clinical validation studies.